[
    [
        {
            "time": "2018-03-08",
            "original_text": "M&A, Innovation & New Drugs to Drive Pharma Stocks",
            "features": {
                "keywords": [
                    "M&A",
                    "Innovation",
                    "New Drugs",
                    "Pharma Stocks"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "M&A, Innovation & New Drugs to Drive Pharma Stocks",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-08",
            "original_text": "Want to be a Buy and Hold Investor? 3 Strategies",
            "features": {
                "keywords": [
                    "Buy",
                    "Hold",
                    "Investor",
                    "Strategies"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Want to be a Buy and Hold Investor? 3 Strategies",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-08",
            "original_text": "Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta",
            "features": {
                "keywords": [
                    "Biotech Stock",
                    "Regeneron",
                    "sBLA",
                    "Biogen",
                    "Withdraw",
                    "Zinbryta"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-08",
            "original_text": "Multimillion-dollar drug yanked from market connected to dangerous brain inflammation cases in U.S.",
            "features": {
                "keywords": [
                    "drug",
                    "yanked",
                    "market",
                    "brain inflammation",
                    "U.S."
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Multimillion-dollar drug yanked from market connected to dangerous brain inflammation cases in U.S.",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-08",
            "original_text": "Key Updates on BMY’s Reyataz and Hepatitis C Franchise",
            "features": {
                "keywords": [
                    "BMY",
                    "Reyataz",
                    "Hepatitis C",
                    "Franchise"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Key Updates on BMY’s Reyataz and Hepatitis C Franchise",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-08",
            "original_text": "Validea John Neff Strategy Daily Upgrade Report - 3/8/2018",
            "features": {
                "keywords": [
                    "Validea",
                    "John Neff",
                    "Strategy",
                    "Daily Upgrade Report"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Validea John Neff Strategy Daily Upgrade Report - 3/8/2018",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 3,
                "Impact": 2,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 2,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 2
            }
        }
    ]
]